ABSTRACT The aim of this study in 2006-08 was to determine the prevalence and risk factors of CVD in an Iranian population of patients with type 2 diabetes mellitus. History and physical examinations were recorded and laboratory tests were performed in 752 patients attending the Mashhad Endocrine and Metabolism Research Center. The prevalence of CVD was 20.1%. CVD was significantly associated with age, duration of diabetes, hypertension, diabetic retinopathy, metabolic syndrome, renal insufficiency, triglycerides, high-density lipoprotein (HDL) cholesterol, uric acid and triglycerides/HDL ratio. Using a logistic regression model, age, metabolic syndrome and HDL cholesterol were significant independent predictors of CVD. The high prevalence of CVD in Iranian patients with type 2 diabetes underscores the importance of better detection and treatment of metabolic risk factors of CVD in these patients. 
‫اإلسالمية‬ ‫إيران‬ ‫مجهورية‬ ‫يف‬ ‫مشهد‬ ‫مدينة‬ ‫يف‬ ‫الثاين‬ ‫النمط‬ ‫من‬
In patients without CVD, the CHD risk at 10 years was estimated using the UK Prospective Diabetes Study risk engine [11] and patients' risk score was then grouped as: < 10% (low risk), 10%-19% (moderate risk) and ≥ 20% (high risk) for CHD.
Hypertension was defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg in the resting position for at least for 30 minutes on 2 different occasions or history of hypertension and receiving antihypertensive drugs. The presence of retinopathy was evaluated by fundoscopic examination by an expert ophthalmologist. Obesity was defined as BMI > 30 kg/m 2 . Abdominal obesity was waist circumference ≥ 102 cm in males and ≥ 88 cm in females. Metabolic syndrome was defined according to the Adult Treatment Panel III criteria as the presence of 3 or more of its 5 components (elevated blood pressure, elevated serum triglycerides, high waist circumference, high plasma glucose and low HDL) [12] .
Laboratory tests
Total cholesterol, triglycerides (TG) and high-density lipoprotein (HDL) cholesterol were measured by the enzymatic method (ParsAzmon). Low-density lipoprotein (LDL) cholesterol was calculated according to the Friedwald formula [LDL= total cholesterol - (HDL + TG/5)]. Non-HDL cholesterol was calculated by the difference between total cholesterol and HDL. TG/HDL cholesterol ratio was calculated for assessment of the level of dense LDL, a relatively novel lipoprotein index that could serve as a good predictor of CHD [13, 14] . The cut-offs for abnormal levels were: TG ≥ 150 mg/dL, total cholesterol ≥ 200 mg/dL, HDL cholesterol ≤ 40 mg/dL males or ≤ 50 mg/dL females, non-HDL cholesterol ≥ 130 mg/dL, LDL cholesterol ≥ 100 mg/dL, TG/HDL cholesterol ≥ 3.
All patients were diabetics on treatment and fasting blood sugar (FBS) was measured routinely by the glucose oxidase method (Human GmbH).
Glycated haemoglobin (HbA1C) was assessed by column chromatography (Biosource), using a cut-off of > 7% for abnormal levels.
Urine albumin in spot urine was measured by immunoturbidometry assay (ParsAzmon). Urine creatinine was measured by enzymatic colorimetric assay normal cut off > 20-25 mg/kg in males and 15-20 mg/kg in females). Uric acid was measured by enzymatic method and hyperuricaemia was defined as the serum levels > 7.0 mg/dL in men and > 5.5 mg/dL in women. Blood urea nitrogen was assessed by colorimetric method with normal range between 5-20 mg/dL. Albumin excretion was determined by calculation of the albumin to creatinine ratio in spot urine test on a fresh early morning sample, and microalbuminuria was defined as a ratio 30-300 mg/g and macroalbuminuria as the ratio > 300 mg/g in 2 out of 3 measurements. Creatinine clearance was detected using the Crockcroft-Gault formula. Normal renal function was defined by creatinine clearance > 90 mL/min/1.73 m 2 and renal insufficiency by creatinine clearance < 60 mL/min/1.73 m 2 .
Data analysis
Statistical analyses were performed by SPSS, version 16. Data was expressed as mean and standard deviation (SD). Non-normal variables were compared by Mann-Whitney U-test. Other variables were tested by either one-way ANOVA or Student t-test. Categorical variables were compared by the chisquared test. Variables with a statistically significant difference between the CVD and non-CVD groups were evaluated by multiple logistic regression with forward stepwise analysis to identify independent risk factors for CVD. P-values <0.05 were considered significant.
Results
A total of 752 patients (355 males and 397 females) with type 2 DM were analysed. Their mean duration of DM was 7.9 (SD 6.4) years. The clinical and biochemical characteristics of the study group are shown in Table 1 . Overall 151 (20.1%) of our patients had CVD. The mean CHD risk score in patients without CVD was 19.9% (SD 13.2%).
The prevalence of CVD risk factors in the total sample is shown in Table 2 . Hypertension or history of hypertension was observed in 51.6% of our patients and blood pressure under optimal control (< 130/80 mmHg) was only detected in 21.0% of the sample. Obesity was found in 25.7% and abdominal obesity in 45.8%. A high proportion of our patients (73.5%) had metabolic syndrome. Diabetic retinopathy was found in 14.3%. Three-quarters (75.0%) had HbA1C > 7%. Lipid abnormalities were prevalent in a large number of our patients; 95.2% had high total cholesterol and 86.9% had low HDL cholesterol. The prevalence of microalbuminuria (21.5%), macroalbuminuria (1.6%) and renal insufficiency (36.7%) were high. Table 3 shows the prevalence of risk factors in patients with and without CVD. The CVD group were significantly older [58.2 (SD 10.3) versus 51.3 (SD 10.7) years] and had a longer duration of DM [10.5 (SD 3.4) versus 7.3 (2.7) years] (P < 0.001) than the non-CVD group. The prevalence of hypertension was 78.1% in the CVD group and 44.9% in the non-CVD group (P < 0.001). The prevalence of metabolic syndrome (80.1% versus 71.9%) (P = 0.04) and of diabetic retinopathy (20.7% versus 12.8%) were also significantly higher in the CVD group (P = 0.01). Concerning the laboratory data, there were statistically significant differences between the CVD and non-CVD sub-groups in the mean levels of blood urea nitrogen, creatinine, triglycerides, HDL cholesterol, TG/HDL ratio, uric acid and glomerular filtration rate (Table 3) .
Of patients with 5 components of metabolic syndrome, 25.6% had CVD compared with 12.2% of patients with 1 component of metabolic syndrome (P = 0.003).
After stratification of the patients according to CHD risk scores (< 10%, 10%-20% and ≥ 20%) in the patients without CHD (Table 4) , the following variables were significantly different between risk groups: age, sex, duration of DM, hypertension, metabolic syndrome, retinopathy, microalbuminuria, HbA1C, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, TG/HDL ratio, uric acid, non-HDL cholesterol, blood urea nitrogen, creatinine and glomerular filtration rate (P < 0.05). Smoking, waist circumference and FBS level were not significantly different between the groups.
The results of stepwise multiple logistic regression showed that the independent risk factors for CVD were age, total cholesterol level, HDL cholesterol level and presence of metabolic syndrome, with an actual number of 322 patients having all these risk factors (Table 5 ).
Discussion
The prevalence of CHD in a large sample of the Iranian population (the in males and 27.2% in females) [18] . Studies in other countries have reported a prevalence of CHD up to 55% among adult type 2 DM patients [19, 20] . The prevalence of CVD in our type 2 DM patients was slightly lower than in another study from the Islamic Republic of Iran study reporting a prevalence of CVD of 28% in type 2 diabetic patients [15] . Although optimal glycaemic control (HbA1C < 7%) must be a target for prevention of micro- and macrovascular complications in patients with type 2 DM, 75.0% of our patients had HbA1C > 7%. Poor glycaemic control was much higher in our patients compared with other studies [21, 22] . Jurado et al. in the North Catalonia Diabetes Study, for example, showed that 56.9% ‫املتوسط‬ ‫لرشق‬ ‫الصحية‬ ‫املجلة‬ ‫عرش‬ ‫السابع‬ ‫املجلد‬ ‫التاسع‬ ‫العدد‬ of their patients had good control of diabetes (HbA1C < 7%) [21] . In the present study, no significant difference was found in FBS and HbA1C levels between CVD and non-CVD groups. Good blood pressure control in DM is associated with reduced risk of CVD [23] . Hypertension or history of hypertension was recorded in 51.6% of our patients and blood pressure under optimal control was only found in 21.0% of the sample. This finding is in agreement with Jurado et al.'s study, which found only 19.7% of patients had blood pressure under control [21] . Similar to other studies we found a significant association between high blood pressure and CVD.
Dyslipidaemia is a known major risk factor for CVD in DM [23] . Lipid abnormalities were found in a large number of our patients. Total cholesterol, TG levels and TG/HDL ratio were significantly higher and HDL cholesterol levels significantly lower in patients with CVD compared with the non-CVD group. This result is similar to another study that reported a dyslipidaemia prevalence of 77.7% in type 2 DM [21] .
Almost three-quarters of our patients (73.5%) had metabolic syndrome, which is similar to other studies. In Ireland a small study of type 1 and 2 DM patients attending for annual review showed that 61.0% patients had metabolic syndrome, more patients with type 2 (69.5%) than type 1 DM (22.2%) [24] . A study in Australian reported that the overall prevalence of metabolic syndrome was 72.3% in a large sample of subjects with type 2 DM [24, 25] . The prevalence of metabolic syndrome was significantly higher in the CVD group (80.1% versus 71.9%). All the components of metabolic syndrome are considered to be independent risk factors for CVD [26] . We showed a significant difference in the number of components of metabolic syndrome in CVD versus non-CVD groups and metabolic syndrome was also an independent risk factor for CVD. Considering this result, control of metabolic syndrome components seems to be important for prevention of CVD in patients with type 2 DM.
Microalbuminuria and nephropathy are associated with increased risk of CVD in clinical studies [27, 28] . In our patients the prevalence of microalbuminuria (21.5%), macroalbuminuria (1.6%) and renal insufficiency (36.7%) were high. The association of microalbuminuria with CVD was not significant but the urine albumin to creatinine ratio differed significantly between CHD risk groups. Albuminuria was significantly higher in the high risk group (risk score > 20%) compared with the moderate (risk score 10%-20%) and low risk (risk score < 10%) groups. Different studies have documented a significant association between chronic kidney disease and increased risk of CVD [29, 30] . In our study the prevalence of CVD was higher in patients with low GFR and a significant difference was found in the prevalence of renal insufficiency between patients with and without CVD. This result is consistent with other studies demonstrating that GFR is a prognostic factor for CVD in DM [29, 31] . Previous studies evaluating the role of uric acid in atherosclerosis have shown conflicting results [32, 33] . In the present study the association between CVD and uric acid was significant but uric acid was not an independent risk factor for CVD. This association is consistent with a meta-analysis of uric acid and CHD [34] .
A positive association was found between the presence of retinopathy and CVD in our study. Poor glycaemic control and high blood pressure contribute to retinopathy as a sign of microvascular disease and CVD as a sign of macrovascular disease in DM. In other studies, retinopathy is correlated with the presence of CVD [35] .
The results showed that the prevalence of CVD and insufficient control of CVD risk factors among our patients was high. These findings are in agreement with other studies in different regions [21, 22] . More aggressive interventions are crucial for patients with DM, including better patient education and more aggressive control of glycaemia, hypertension, hyperlipidaemia and metabolic syndrome. 
